
DSGN: Is Design Therapeutics, Inc. Halal?
Design Therapeutics, Inc.
$14.99
-3.66%
Market Cap: 936.2M
Compliance Status
Halal
Screened on Sep 1, 2026 · AAOIFI Standard 21
Very Good
Is Design Therapeutics, Inc. (DSGN) halal? Halal. Based on AAOIFI screening, Design Therapeutics, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 80/100 (Grade: A).
Quote this verdict
HalalScreener rates Design Therapeutics, Inc. (DSGN) Halal, 80/100, grade A under AAOIFI Standard 21, screened Sep 1, 2026. Source: https://halalscreener.app/en/stock/DSGN
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
What this means for you
You can own DSGN
It passes both the business activity and financial ratio screens under AAOIFI Standard 21.
Purification amount is Pro
We have screened DSGN's prohibited income, but the exact share you would need to purify is part of Pro.
About Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Sector: Healthcare · Industry: Biotechnology
Shariah Compliance Status
Compliance History
Halalnow
since Aug 2026
Under Review
until the change above
Not Halal
until the change above
Tracked since Jun 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Track DSGN and 6,200+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Frequently Asked Questions
Is Design Therapeutics, Inc. (DSGN) halal to invest in?
Why did Design Therapeutics, Inc. get a A compliance rating?
What could change Design Therapeutics, Inc.'s Shariah verdict?
How often is Design Therapeutics, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.